Cryo-Cell International (CCEL) Co-CEO reports 75,000 new stock options and updated holdings

Rhea-AI Filing Summary

Cryo-Cell International Co-CEO Mark Portnoy reported new stock option grants and updated his holdings in company securities. On January 7, 2026, he was granted a stock option for 50,000 shares of common stock at an exercise price of $3.89 per share, expiring on January 7, 2031. This grant, made under the Cryo-Cell 2022 Stock Incentive Plan, is split into three equal tranches that each require both time-based vesting and stock price hurdles of $6, $8, and $10 per share over 20 consecutive trading days.

Portnoy also received a separate stock option for 25,000 shares at an exercise price of $3.89 per share, expiring January 7, 2031, which vests one-third upon issuance, one-third on January 7, 2027, and one-third on January 7, 2028. Following these grants, he reports 821,973 common shares held directly, 42,266 shares held indirectly via a 401(k), and 71,529 shares held indirectly by Capital Asset Fund #1 Limited Partnership, where he may be deemed a beneficial owner as general partner.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Portnoy Mark L.

(Last) (First) (Middle)

700 BROOKER CREEK BLVD

SUITE 1800

(Street)

OLDSMAR FL 34677

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRYO CELL INTERNATIONAL INC [ CCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Co-CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								821,973	D
Common Stock								42,266	I	By 401K
Common Stock								71,529	I	By Partnership(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$7.53							08/30/2019	08/30/2029	Common stock	22,222		22,222	D
Stock Option	$7.28							12/20/2019	12/20/2029	Common Stock	20,000		20,000	D
Stock Option	$12.27							12/22/2021(2)	12/22/2028	Common Stock	100,000		100,000	D
Stock Option	$4.77							01/03/2023(3)	01/03/2028	Common Stock	25,000		25,000	D
Stock Option	$4.3							12/23/2022	12/23/2027	Common Stock	25,000		25,000	D
Stock Option	$6.47							12/22/2023(4)	12/22/2028	Common Stock	25,000		25,000	D
Stock Option	$8.08							01/21/2025(5)	01/21/2030	Common Stock	25,000		25,000	D
Stock Option	$3.89	01/07/2026		A		50,000		01/07/2026(6)	01/07/2031	Common Stock	50,000	$3.89	50,000	D
Stock Option	$3.89	01/07/2026		A		25,000		01/07/2026(7)	01/07/2031	Common Stock	25,000	$3.89	25,000	D

Explanation of Responses:

1. Shares of common stock held by Capital Asset Fund #1 Limited Partnership, as to which Mark Portnoy may be deemed beneficial owner as its general partner.

2. Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term.

3. 8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026.

4. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.

5. Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027.

6. The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.

7. Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.

	/s/ Mark Portnoy	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Cryo-Cell International (CCEL) report for Mark Portnoy?

The report shows that Mark Portnoy, a director, Co-CEO and 10% owner of Cryo-Cell International, received new stock option grants on January 7, 2026 and updated his direct and indirect holdings of the company’s common stock and options.

How many new stock options did Mark Portnoy receive and at what exercise price?

On January 7, 2026, Portnoy was granted two sets of stock options: one for 50,000 shares and another for 25,000 shares, each with an exercise price of $3.89 per share and an expiration date of January 7, 2031.

What are the vesting conditions for Mark Portnoy’s 50,000-share option grant at Cryo-Cell (CCEL)?

The 50,000-share option grant, issued under the Cryo-Cell 2022 Stock Incentive Plan, is divided into three equal tranches. Each tranche vests after its respective one-, two-, and three-year anniversaries and requires the stock to reach average closing prices of at least $6, $8, and $10 per share over 20 consecutive trading days, subject to Portnoy’s continued service.

How do the 25,000 new stock options granted to Mark Portnoy vest?

The separate 25,000-share stock option grant at an exercise price of $3.89 per share vests one-third upon issuance, one-third on January 7, 2027, and one-third on January 7, 2028, assuming continued service.

How many Cryo-Cell (CCEL) common shares does Mark Portnoy beneficially own after these transactions?

After the reported transactions, Portnoy reports 821,973 shares of Cryo-Cell common stock held directly, 42,266 shares held indirectly via a 401(k), and 71,529 shares held indirectly by Capital Asset Fund #1 Limited Partnership, where he may be deemed a beneficial owner as its general partner.

What existing stock options does Mark Portnoy hold in Cryo-Cell International?

Portnoy holds multiple existing stock option positions, including options on 22,222, 20,000, 100,000, 25,000, 25,000, and 25,000 shares with exercise prices ranging from $4.30 to $12.27 per share and expiration dates between 2019 and 2030, each with specified vesting schedules.